Given the success of Research Topic
Mechanisms of Epigenetics and Genetics in Leukemogenesis and the rapidly evolving subject area, we are pleased to announce the launch of Volume II.
Since the beginning of the 21st century, epigenetics has entered a period of rapid development, especially in the field of biology and medicine. More and more clinical drugs have been found and approved. However, these clinical drugs can only target limited patient profiles. There is a huge heterogeneity in various tumors, for which higher requirements for the basic research of clinical problems are needed. From the public to academia, epigenetics research has been accumulating attention, which makes it necessary to further examine the progress and significance of epigenetics development. Despite that epigenetic drugs have unique advantages in the clinical treatment of hematological malignancies, such as Leukemia, research on genetics and epigenetics in the mechanisms, pathogenesis and prognosis of hematological malignancies still needs to be further strengthened and deepened.
This research topic aims to elucidate the recent progress and advances in the mechanism of occurrence, drug resistance and relapse of acute leukemia from the perspective of genetics and/or epigenetics as well as their synergy and network regulation, and to explore the clinical application in prognosis and therapeutic strategy, especially for some particular subtypes of acute leukemia, such as AML1-ETO, PML-RARA and Bcr-Abl.
We welcome submissions of Original Research, Reviews, Case Reports, Editorials, Perspectives, Commentaries, Technical Notes and more, on the subtopics below:
1) The interaction between genetic and epigenetic regulation in the development of leukemia and the downstream targets
2) Genetic and epigenetic regulation in chemotherapy resistance of leukemia and the signaling pathways
3) The role of mRNA epigenetic modification as well as DNA epigenetic modification in the occurrence and development of leukemia
4) Genetic and epigenetic techniques for prognosis prediction and therapy guide of leukemia.
5) The mechanism of genetic and epigenetic drugs in the treatment of leukemia
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
